Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
|Articles|May 6, 2014
Rapid Micro Biosystetms
Rapid Micro Biosystems helps companies in the pharmaceutical, biotech, and personal care products industries automate and accelerate their microbial quality control testing, often a gating factor to product release.
Advertisement
With offices in the US and Europe, Rapid Micro Biosystems has a singular focus on providing businesses a technology for automated rapid detection through the Growth Direct™ System.
The Growth Direct™ System, by Rapid Micro Biosystems, automates the detection and enumeration of colonies in microbial quality control in manufacturing. The system includes 2 incubators, robotics and imaging systems that detect and enumerate microbial growth in about half the time of the traditional method. By using the natural autoflouresence of living cells, the system “sees” colonies forming at about 100 cells, far sooner than the human eye. This allows the technology to provide results in about half the time of the traditional method while preserving the colony.
The Growth Direct™ System is designed to be a single test method for use with all the key tests in the microbial quality control lab including bioburden testing, environmental monitoring and sterility testing. Sample preparation closely matches the existing tests, simplifying training of technicians. The technology can support all tests within one instrument, or each test within a separate unit.
Contact Details:
Company Name: Rapid Micro Biosystems
Address: One Oak Park Drive, Bedford, MA (USA)
Tel: +1 781 271 1444
Fax: +1 781 271 9905
Web:
Contact: Mark Severns
Email: sales@rapidmicrobio.com
Advertisement
Related to this article
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
This article discusses risk-based lifecycle governance, system implementation considerations, and the progression of batch record control from paper-based to fully electronic systems.
Advertisement
Advertisement